Electrospinning

Integer to Exhibit at 2023 MD&M West Expo, February 7 – 9

Retrieved on: 
Thursday, February 2, 2023
MDO, Lead, MD, NYSE, Integer, PTFE, Electrophysiology, Miniaturization, Dominican Republic, Anaheim Convention Center, Partnership, Catheter, Electrospinning, Medical device, Medical imaging

Attendees are invited to visit Integer at booth #1759 to learn more about Integer’s range of innovative end-to-end medical device design, development and manufacturing solutions.

Key Points: 
  • Attendees are invited to visit Integer at booth #1759 to learn more about Integer’s range of innovative end-to-end medical device design, development and manufacturing solutions.
  • This encompasses expanded offerings as a result of the acquisitions of Aran Biomedical in April 2022, and Oscor in December 2021.
  • Integer solutions include components, sub-assemblies, manufacturing transfers, custom development and finished devices.
  • It also meets high current pulsing demands to provide up to 50 percent improved runtimes for new advanced devices with Bluetooth communication.

Ultra-clean biomedical nanofiber production now available from Nanoscience Instruments

Retrieved on: 
Thursday, December 16, 2021
Electrospinning, FDA, Immune electron microscopy, Gaps, HEPA, Microscopy, Doctor of Philosophy, Small Business Saturday, Industry, Solvent, Heating, ventilation, and air conditioning, Quartz, Temperature, CGMP, TEM, Paediatric-use marketing authorisation, Workflow, SEM, Sterilization, Medical device, Wood drying

PHOENIX, Dec. 16, 2021 /PRNewswire-PRWeb/ -- Nanoscience Instruments introduces the new biomedical Fluidnatek electrospinning systems into the US Market.

Key Points: 
  • PHOENIX, Dec. 16, 2021 /PRNewswire-PRWeb/ -- Nanoscience Instruments introduces the new biomedical Fluidnatek electrospinning systems into the US Market.
  • Nanoscience Instruments Application scientist Francisco J. Chaparro, PhD, has worked extensively with electrospinning systems, from home-built units, to premium, industrial grade systems.
  • Nanoscience Instruments is a trusted supplier of the most innovative and highest quality analytical solutions to academia and industry.
  • The full portfolio is available on the Nanoscience Instruments website: https://www.nanoscience.com/products/

AFYX Therapeutics Presents New Study Showing Therapeutic Antibody Delivery to Oral Mucosa Using Rivelin Biodegradable Mucoadhesive Patch

Retrieved on: 
Tuesday, September 7, 2021
Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Rivelin Patch Technology, AFYX Therapeutics, RIVELIN PATCH TECHNOLOGY, AFYX THERAPEUTICS

The preclinical study demonstrated for the first time that the companys Rivelin technology is capable of delivering biologic drugs.

Key Points: 
  • The preclinical study demonstrated for the first time that the companys Rivelin technology is capable of delivering biologic drugs.
  • AFYX has developed the Rivelin patch for delivery of therapeutics to wet tissue surfaces such as the oral mucosa.
  • The recent presentation features the first Rivelin study demonstrating the potential to deliver not only small molecules but also proteins in this case anti-TNF antibody fragments.
  • A copy of the presentation, titled Delivery of Therapeutic F(ab) antibody fragments to the Oral Mucosa Using Electrospun Patches, is available on AFYXs website at https://afyxtx.com/#publications .

IME Medical Electrospinning announces name change to VIVOLTA

Retrieved on: 
Tuesday, September 7, 2021

LEIDEN, Netherlands, Sept. 7, 2021 /PRNewswire/ -- VIVOLTA, a global leader in nanofiber-based medical devices, today announced that it has changed its corporate name from IME Medical Electrospinning to VIVOLTA.

Key Points: 
  • LEIDEN, Netherlands, Sept. 7, 2021 /PRNewswire/ -- VIVOLTA, a global leader in nanofiber-based medical devices, today announced that it has changed its corporate name from IME Medical Electrospinning to VIVOLTA.
  • Importantly, the MediSpinplatform, protected by seven patent families, meets the guidelines described in the first ASTM standard for fiber-based medical scaffolds (F3510-21), which VIVOLTA co-authored.
  • VIVOLTA formerly IME Medical Electrospinning is a leader in the field of electrospun nanofiber-based medical devices, tissue engineering products, and drug delivery solutions.Utilizing its fully automated MediSpintechnology platform, production of VIVOLTA's solutions is both consistent, reproducible and scalable.
  • Importantly, the MediSpinplatform, protected by seven patent families, meets the guidelines described in the first ASTM standard for fiber-based medical scaffolds (F3510-21), which VIVOLTA co-authored.

Nanoscience Instruments Announces the Launch of the Spinbox Electrospinning and Electrospraying System

Retrieved on: 
Saturday, July 10, 2021
Nanotechnology, Spinning, Electrospinning, Fume hood, Ventilation, Building engineering, Articles, Technology

PHOENIX, July 9, 2021 /PRNewswire-PRWeb/ --Nanoscience Instruments proudly announces the launch of the Spinbox, an ideal instrument for entry into professional electrospinning systems.

Key Points: 
  • PHOENIX, July 9, 2021 /PRNewswire-PRWeb/ --Nanoscience Instruments proudly announces the launch of the Spinbox, an ideal instrument for entry into professional electrospinning systems.
  • "Spinbox systems can be easily customized to fit the specific needs of each user," explains Francisco J. Chaparro, PhD, Electrospinning Applications Scientist.
  • The Spinbox is a true benchtop electrospinning system , equipped with its own active exhaust system.
  • This unique ventilation system removes harmful solvent vapors from the Spinbox chamber without requiring space under a fume hood.

Confluent Medical Announces Strategic Investment in The Electrospinning Company

Retrieved on: 
Tuesday, May 4, 2021
Engineering, Health, Medical devices, Manufacturing, Cardiology, Textiles, Biotechnology, Nanotechnology, Spinning, Electrospinning, Fibers, Nanofiber, Medtech, Confluence, Articles

b'Confluent Medical Technologies Inc. (Confluent) announced today a strategic investment in The Electrospinning Company Ltd. (Electrospinning).

Key Points: 
  • b'Confluent Medical Technologies Inc. (Confluent) announced today a strategic investment in The Electrospinning Company Ltd. (Electrospinning).
  • Additionally, the application of the textile to the valve frame will be fully automated, simplifying the manufacturing process.\n\xe2\x80\x9cThe investment in Electrospinning reinforces Confluent\xe2\x80\x99s strategy of Applying Materials Science to MedTech Innovation,\xe2\x80\x9d said Dean Schauer, CEO and President of Confluent Medical.
  • Additional information about Confluent is available at www.confluentmedical.com .\nElectrospinning offers contract services to design, develop and manufacture nanofiber biomaterials for medical devices and regenerative medicine.
  • Additional information about The Electrospinning Company is available at www.electrospinning.co.uk .\nFor information please contact Confluent Medical, https://confluentmedical.com/ .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504006122/en/\n'

IME Medical Electrospinning appoints Sander de Vos as Chief Business Officer

Retrieved on: 
Thursday, April 1, 2021
Given names, Nanotechnology, Spinning, Electrospinning, Ime, De Vos, Vos, Sander

WAALRE,Netherlands, April 1, 2021 /PRNewswire/ -- IME Medical Electrospinning, a global leader in electrospun medical devices for tissue rebuilding and regenerative medicine as well as implants and drug delivery solutions,today announced that it has further strengthened its management team with the appointment ofSander de Vos as Chief Business Officer (CBO).

Key Points: 
  • WAALRE,Netherlands, April 1, 2021 /PRNewswire/ -- IME Medical Electrospinning, a global leader in electrospun medical devices for tissue rebuilding and regenerative medicine as well as implants and drug delivery solutions,today announced that it has further strengthened its management team with the appointment ofSander de Vos as Chief Business Officer (CBO).
  • He will be responsible for the worldwide roll-out of the company's medical electrospinning strategy, based on IME's ground-breaking MediSpinXL industrial production platform.
  • Judith Heikoop, CEO of IME Medical Electrospinning comments:
    "We at IME are thrilled to welcome Sander to our fast-growing team of professionals.
  • Sander de Vos (46) is an accomplished executive with more than 15 years of leadership experience across healthcare and biotech commercial and business development positions.

IME Medical Electrospinning appoints Sander de Vos as Chief Business Officer

Retrieved on: 
Thursday, April 1, 2021
Given names, Nanotechnology, Spinning, Electrospinning, Ime, De Vos, Vos, Sander

WAALRE,Netherlands, April 1, 2021 /PRNewswire/ -- IME Medical Electrospinning, a global leader in electrospun medical devices for tissue rebuilding and regenerative medicine as well as implants and drug delivery solutions,today announced that it has further strengthened its management team with the appointment ofSander de Vos as Chief Business Officer (CBO).

Key Points: 
  • WAALRE,Netherlands, April 1, 2021 /PRNewswire/ -- IME Medical Electrospinning, a global leader in electrospun medical devices for tissue rebuilding and regenerative medicine as well as implants and drug delivery solutions,today announced that it has further strengthened its management team with the appointment ofSander de Vos as Chief Business Officer (CBO).
  • He will be responsible for the worldwide roll-out of the company's medical electrospinning strategy, based on IME's ground-breaking MediSpinXL industrial production platform.
  • Judith Heikoop, CEO of IME Medical Electrospinning comments:
    "We at IME are thrilled to welcome Sander to our fast-growing team of professionals.
  • Sander de Vos (46) is an accomplished executive with more than 15 years of leadership experience across healthcare and biotech commercial and business development positions.

Study Published in the European Journal of Oral Sciences Features AFYX Therapeutics’ Rivelin-CLO Patch for the Treatment of Oral Lichen Planus

Retrieved on: 
Thursday, March 11, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Medical Supplies, Organ systems, Steroids, Medical specialties, Autoimmune diseases, Corticosteroids, Lichenoid eruptions, Organochlorides, Lichen planus, Clobetasol, Electrospinning, Rivelin Patch Technology, AFYX Therapeutics

This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.

Key Points: 
  • This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.
  • Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol to treat symptomatic Oral Lichen Planus (OLP) lesions.
  • This new mucoadhesive patch technology holds great promise for the treatment of patients with mucosal diseases.
  • Rivelin is a muco-adhesive two layered patch that delivers a pharmaceutical product (such as clobetasol) directly to wet tissue surfaces.

IME Medical Electrospinning and STENTiT enter into development cooperation on resorbable endovascular support grafts to regenerate vascular tissue

Retrieved on: 
Wednesday, February 10, 2021
Medical technology, Interventional radiology, Medicine, Electrospinning, Nanotechnology, Spinning, Medical device, Stent, Implant, Technology

STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions developing first-of-its-kind regenerative endovascular blood vessel implants.

Key Points: 
  • STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions developing first-of-its-kind regenerative endovascular blood vessel implants.
  • "We are thrilled to join forces with IME Medical Electrospinning to further optimize our fibrillated endovascular implants.
  • IME Medical Electrospinning develops medical devices in close collaboration with an ever-growing portfolio of customers and partners worldwide within the industry, the scientific environment, hospitals and medical institutes.
  • STENTiT is a medical device spin-off company from Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants.